Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Myelodysplastic Syndromes 8Leukemia, Myeloid, Acute 7Leukemia, Myelomonocytic, Chronic 5Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Melanoma 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hematologic Diseases 1Cytopenia 1Carcinoma, Squamous Cell 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cisplatin 76Radiotherapy 44Cetuximab 40pembrolizumab 39Paclitaxel 34Carboplatin 33Docetaxel 30Fluorouracil 25Radiotherapy, Intensity-Modulated 23Nivolumab 18Drug Therapy 14Radiation 12Erlotinib Hydrochloride 9cemiplimab 8Magnetic Resonance Spectroscopy 8Blood Specimen Collection 8130-nm albumin-bound paclitaxel 8durvalumab 7atezolizumab 7Cyclophosphamide 7Afatinib 7Surveys and Questionnaires 6Surgical Procedures, Operative 6Panitumumab 6Leucovorin 6Esophagectomy 6Chemoradiotherapy 6fludarabine 5aldesleukin 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Squamous Cell × cedazuridine × Clear all
NCT06357858 2024-07-03

ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck

Case Comprehensive Cancer Center

Phase 1 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡